arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Oric Pharmaceuticals, Inc.

ORIC
$13.48 ▲ +0.57 (+4.37%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
31 Visible periods
18 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Oric Pharmaceuticals, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.4B
Dividend Yield
Revenue Growth
Op. Margin
ROIC -7.5%
FCF / Share $-0.31
Trailing P/E
Price / Book 3.4x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-35.77M
↓ -19.1%
FCF / Share Free cash flow per share
$-0.31
↑ +33.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 9 years · 31 quarters